Label Update for AstraZeneca's Olaparib Cleared by CDSCO Panel
New Delhi: In a recent regulatory update, the Subject Expert Committee (SEC) under the Oncology division of the Central Drugs Standard Control Organisation (CDSCO) has approved the proposed revision...